Alx Oncology Inc.
Clinical trials sponsored by Alx Oncology Inc., explained in plain language.
-
New drug ALX2004 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called ALX2004 in people with advanced lung, head and neck, colorectal, or esophageal cancers that have stopped responding to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer …
Phase: PHASE1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
New hope for hard-to-treat breast cancer: triple-drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called evorpacept combined with standard treatments (trastuzumab and chemotherapy) for people with advanced HER2-positive breast cancer that has worsened after prior therapy. About 120 participants will receive the combination to see if it shrinks tumo…
Phase: PHASE2 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated May 26, 2026 11:59 UTC